Authors' recommendations: Lymphoid cancers, including B- and T-cell malignancies, are a group of diseases associated with the immune cells in lymphatic tissue, bone marrow, and blood. These cancers include, but are not limited to: chronic and acute leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and mantle cell lymphoma (MCL). Once a specific cancer subtype is identified, targeted treatment options vary according to disease, and may consist of radiation therapy, chemotherapy, targeted therapy, plasmapheresis, biologic therapy, stem cell transplant, and watchful waiting. An important factor in determining success of treatment and monitoring disease progression and prognosis in certain lymphoid cancers is the monitoring of minimal residual disease (MRD), the small numbers of cancerous cells that remain during or following treatment. Development of new technologies using next-generation sequencing (NGS) aim to circumvent the limitations of existing MRD detection technologies and improve the sensitivity of clonal detection in lymphoid cancers. One such technique, the clonoSEQ Process by Adaptive Technologies, provides detection and quantification of MRD for patients with lymphoid cancers.

Project Status: Completed

Year Published: 2017

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=62686

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: Winifred S. Hayes, Inc